Final closing of the placing and capitalisation of loan notes. 18/05/09

Guildford, UK, 18 May 2009: ReNeuron Group plc (LSE: RENE.L) announced on 12 March 2009 its intention to raise up to £3 million via a placing of up to 100,000,000 new ordinary shares of 1 pence each (“Ordinary Shares”) credited as fully paid up at a price of 3 pence per Ordinary Share (the “Placing”). The Company has subsequently announced three successive closings of the Placing, with the issue and allotment of 66,211,111 Ordinary Shares in aggregate as a result.

More…

Third closing of the placing. 14/05/09

Guildford, UK, 14 May 2009: ReNeuron Group plc (LSE: RENE.L) announced on 12 March 2009 its intention to raise up to £3 million via a placing of up to 100,000,000 new ordinary shares of 1 pence each (“Ordinary Shares”) credited as fully paid up at a price of 3 pence per Ordinary Share (the “Placing”). ReNeuron has subsequently announced that shareholder approval of the Placing had been obtained and that on 3 April 2009, 25,611,111 Ordinary Shares were allotted and issued at first closing of the Placing and that a further 23,266,667 Ordinary Shares were allotted and issued on 7 April 2009, at second closing of the Placing.

More…

New data regarding ReNeuron's ReN001 stem cell line for stroke to be presented at US conference. 01/05/09

Guildford, UK, 1 May 2009: ReNeuron Group plc (LSE: RENE.L) today announces further data concerning the pre-clinical characterisation and mode of action of ReNeuron’s lead ReN001 neural stem cell line for stroke. The studies were conducted by Professor Paul Sanberg and colleagues at the Center of Excellence for Aging and Brain Repair, Department of Neurosurgery, University of South Florida College of Medicine (part of USF Health), Tampa, Florida, USA.

More…

ReNeuron successfully automates its stem cell manufacturing process. 09/04/09

Guildford, UK, 9 April 2009: ReNeuron Group plc (LSE: RENE.L) today announces the publication of a paper in the journal Biotechnology Letters* demonstrating successful automation of the manufacturing of its ReN001 neural stem cell line for stroke.

More…

Second closing of the placing. 07/04/09

Guildford, UK, 7 April 2009: ReNeuron Group plc (LSE: RENE.L) announced on 12 March 2009 its intention to raise up to £3 million via a placing of up to 100,000,000 new ordinary shares of 1 pence each (“Ordinary Shares”) credited as fully paid up at a price of 3 pence per Ordinary Share (the “Placing”).

More…

ReNeuron announces positive pre-clinical data with lead stem cell line in peripheral arterial disease . 06/04/09

Guildford, UK, 6 April 2009: ReNeuron Group plc (LSE: RENE.L) today announces positive pre-clinical efficacy data with its lead CTX stem cell line in a model of peripheral arterial disease (PAD).This is a chronic and debilitating disease that progressively restricts blood flow in the limbs, causing cramping, chronic pain and in extreme cases, loss of limb. PAD is commonly associated with other conditions such as diabetes, obesity and stroke. At least 1 in 20 people over the age of 55 have some degree of PAD and it becomes more common with increasing age.

More…

Result of EGM and first closing of the placing. 03/04/09

Guildford, UK, 3 April 2009: ReNeuron Group plc (LSE: RENE.L) announced on 12 March 2009 its intention to raise up to £3 million via a placing of up to 100,000,000 new ordinary shares of 1 pence each (“Ordinary Shares”) credited as fully paid up at a price of 3 pence per Ordinary Share (the “Placing”).

More…

ReNeuron Announces Fundraising and Conversion of Loan Notes. 12/03/09

Guildford, UK, 12 March 2009: ReNeuron Group plc (LSE: RENE.L) announces that it proposes to raise up to £3 million via a placing of up to 100,000,000 new ordinary shares of 1 pence each (“Ordinary Shares”) credited as fully paid up at a price of 3 pence per Ordinary Share (the “Placing”). Commitments from placees have already been received in respect of 92,766,667 Placing Shares, representing gross proceeds of £2.78 million.

More…

ReNeuron signs licence agreement with BioFocus DPI. 26/01/09

Guildford, UK, 26 January 2009: ReNeuron Group plc (LSE: RENE.L) today announces that it has signed a licence with BioFocus DPI, the service division of Galapagos NV. Under the licence, ReNeuron will make available to BioFocus DPI one of its neural stem cell lines derived from the striatum, the region of the brain most commonly affected by Huntington’s disease (HD). BioFocus DPI researchers will use the cell line to validate HD drug targets that were discovered by BioFocus DPI. The research is being conducted by BioFocus DPI on behalf of CHDI Foundation, Inc., a US-based non-profit organisation whose mission is to rapidly discover and develop drugs that delay or slow the progression of Huntington’s disease. ReNeuron will receive licence fees for the provision of the cell line for this purpose.

More…

ReNeuron clarifies press comments . 21/01/09

Guildford, UK, 21 January 2009: ReNeuron Group plc (LSE: RENE.L) has noted certain comments made in the press following the Company’s announcement on 19 January concerning UK regulatory approval to commence an initial clinical trial with its ReN001 stem cell therapy for stroke. The Company would like to make the following statements relating to these comments by way of clarification:

More…